政策护航让创新药用得上付得起

Core Insights - The recent adjustments to the national medical insurance drug list focus on the health of the population, establishing a comprehensive access mechanism to support innovative drugs, benefiting patients and enhancing the competitiveness of the pharmaceutical industry [1][3][5] Group 1: National Medical Insurance Drug List - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 Class 1 innovative drugs, achieving an overall success rate of 88%, a significant increase from 76% in 2024 [1] - The introduction of 19 drugs into the first version of the commercial insurance innovative drug list is expected to enhance the clinical application of innovative drugs and improve multi-payment capabilities [1][4] Group 2: Support for Original Innovation - A significant portion of medical expenses is attributed to drug costs, with many effective new drugs still relying on imports, highlighting the need for strengthening basic research and core technology breakthroughs to foster a favorable environment for original innovation [2] - Since the implementation of the "44 Document" in 2015, the number of clinical trial applications for domestically developed innovative drugs has increased 12-fold, marking a transition from a focus on generic drugs to innovation-driven development [3] Group 3: Integration of Insurance Systems - The establishment of a commercial insurance innovative drug list will clarify the boundaries of basic medical insurance coverage, integrating funds from both insurance systems to enhance health protection for the population [4] - The "dual list" reform signifies a breakthrough in the multi-tiered medical security system, transitioning from basic survival coverage to health value protection, providing a unique Chinese solution to global accessibility challenges for innovative drugs [4]